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Since its launch in 2005, the European Liver Patients’
Association (ELPA) has worked to promote the interests
of people with all forms of liver disease. Despite
improvements in medical treatment, and despite the
recent publication of WHO guidelines for screening, the
overall situation of hepatitis C virus (HCV) transmission
in Europe is a growing concern for ELPA. Many patients
who are infected with HCV can carry the infection for
many years before developing symptoms [1], and people
who currently have chronic HCV will represent a heavy
disease burden in the coming years [2]. The World
Health Organization (WHO) estimates that more than
19 million people in Europe are infected with Hepatitis
C, and states that transmission is mainly concentrated
in people who inject drugs (PWID), who globally have
67% HCV prevalence [3].
Since there is no vaccine for Hepatitis C, prevention
efforts must concentrate on health education programmes
targeting high-risk populations and on public awareness
campaigns that seek to improve testing and case finding in
the general community [1].
On 1 December 2010, World AIDS Day, the European
Monitoring Centre for Drugs and Drug Addiction
published guidelines on testing for HIV, viral hepatitis and
other infectious diseases in PWID. The new guidelines
recommended a strategy to increase the uptake of testing
among PWID in Europe and beyond. This would enable
earlier treatment of infected individuals and reduce the
further spread of the disease [4].
Two years later, the Euro Hepatitis Care Index called
attention to the need for screening programs in risk
populations to be improved in all countries, noting that
in order to increase testing in drug users it is impor-
tant to make the services as reachable and convenient
as possible [1]. More recently, WHO recommended
screening to identify persons with HCV infection, and
also recommended that HCV testing be offered to indivi-
duals who have a history of HCV risk behaviour or who
belong to populations with high HCV prevalence [3].
There is evidence that where HCV screening of PWID is
implemented, it can be cost-effective [5] and screening
programmes can be successful [6]. However it is not clear
which countries have adopted these guidelines and there
are still relatively few published reports on best practices.
Identifying infected patients through screening pro-
grammes is only part of the solution, and ELPA continues
to be concerned about the slow introduction of new drugs
for HCV treatment. The Euro Hepatitis Care Index
showed that general access to the direct-acting antiviral
drugs telaprevir and boceprevir only existed in five
European countries, and that one-third of countries were
not providing these new drugs at all [1]. WHO states that
avoiding discrimination or stigmatisation of PWID is
essential, and reports that treatment for HCV infection is
both efficacious and cost-effective in PWID. WHO recom-
mends that all adults and children with chronic HCV
infection, including PWID, be assessed for antiviral treat-
ment. WHO also notes that treatment may be effective as
prevention due to a reduction in transmission [3].
In order to bring about change and to ensure that guide-
lines and effective treatment programmes are implemen-
ted in Europe, ELPA will continue to call for the reporting
of additional data on HCV screening and treatment mea-
sures. We look forward to further changes being made in
European policies and healthcare strategies which lead to
success in tackling this chronic disease.
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